The West is fostering India as an alternative to reduce dependence on China’s supply chain and as a strategic ally to counter China’s political and economic dominance.’ Explain this statement with examples.
This question is available to read here. The practice button generates a fresh question from the same paper. Here, practise an answer plan in keywords. Choose your timer on the next screen. Feedback uses our common 15-point practice rubric, rather than the paper’s original mark allocation.
President Donald Trump’s high-profile reception of Chinese President Xi Jinping, marked by a ceremonial red carpet and a powerful military flyover featuring B-1 strategic bombers, underscores the intricate dance of deterrence and dialogue shaping contemporary US-China relations. This summit-level engagement highlights how modern superpowers balance intense geopolitical competition with the persistent necessity of direct communication to manage global stability.
On September 20, 2026, a new border pact between Pakistan and China was officially announced, aimed at formalizing administrative arrangements along their shared frontier. While the agreement is presented by the signatories as a technical demarcation effort, it directly concerns disputed territories in the Kashmir region, which India considers an integral part of its sovereign territory. The development has drawn immediate diplomatic objection from New Delhi, as it challenges India's historical claims and signifies a deepened strategic nexus between Islamabad and Beijing. This event highlights the evolving geopolitical dynamics in the Himalayas, where bilateral agreements are increasingly utilized to assert territorial control and strengthen regional partnerships.
On September 29, 2026, the United States announced a zero-percent tariff regime for specific categories of speciality drugs imported from 20 nations, including India. This policy adjustment targets life-saving pharmaceutical segments, including gene therapies, cell therapies, antibody-drug conjugates, rare disease medications, and infertility treatments. By removing tariff barriers for these complex medical products, the U.S. aims to diversify its pharmaceutical supply chains and lower costs for advanced healthcare. For India, the 'pharmacy of the world', this decision creates a significant incentive to transition beyond traditional generic manufacturing toward high-value biopharmaceuticals and complex medicinal components.